The U.S. labor market faced its toughest year since the pandemic in 2025, with layoffs soaring to 1.2 million. Economists warn of an 'uncomfortably slow' rebound in 2026, leaving job seekers navigating a landscape of fierce competition and hiring freezes.
Europe relies on China for the rare earth elements essential in transition technologies, but it's making a late bid to end dependency.
Producer prices rose 0.5% last month, exceeding forecasts and marking the quickest pace in three months, as a sharp jump in services costs offset stable goods prices, signaling persistent inflationary pressures in the pipeline.
ARK Invest's founder capitalized on recent market weakness to increase holdings in three of her flagship disruptive innovation picks, signaling continued conviction despite sector volatility.
In its Q4 2025 letter, Greenlight Capital revealed a new position in dental distributor Henry Schein (HSIC), arguing the stock presents an opportunity for operational improvement and shareholder returns, despite recent underperformance.
A campaign-trail proposal to temporarily cap credit card interest at 10% could offer significant savings for millions of borrowers, but experts warn of potential unintended consequences for credit access and long-term financial health.
In a landmark deal, AstraZeneca has licensed a suite of next-generation weight-loss drugs from China's CSPC, aiming to challenge the dominance of Lilly and Novo Nordisk with longer-acting monthly injectables.
The AI-as-a-Service (AIaaS) market is witnessing significant growth, fueled by cloud innovation and corporate demand for scalable AI solutions. While data privacy remains a hurdle, the integration of generative AI and tailored platforms is accelerating adoption across industries.
As Eli Lilly prepares to report its Q4 and full-year 2025 results on February 4th, investors are weighing whether the pharmaceutical giant's premium valuation leaves room for a positive surprise, or if the stock is priced for perfection.
Newly launched oral weight-loss drug Wegovy from Novo Nordisk recorded more than 26,000 U.S. prescriptions in its second full week, signaling robust early demand as competition with Eli Lilly intensifies.
Consumer staples giant Church & Dwight (NYSE:CHD) reported fourth-quarter revenue in line with Wall Street expectations, though underlying organic sales showed signs of stagnation. The company's gross margin outperformance provided a bright spot, lifting shares post-earnings.
Amid market volatility, these three companies offering yields above 4% present a compelling case for income-focused investors, backed by strategic pivots and resilient business models.
Shares of Lionsgate Studios Corp. receive a vote of confidence from Seaport Research, which raised its price target following strong box office results. The move underscores broader analyst support for the newly independent content company's library monetization and strategic use of AI.
Fresh Israeli military actions in central and southern Gaza have resulted in multiple casualties, testing the durability of a months-long, U.S.-brokered truce and hindering critical aid flows.
From economic despair to demands for fundamental rights, Iran's recent wave of protests revealed a rare, broad-based defiance. Through the eyes of those who were there, a story emerges of fleeting hope shattered by a security response activists call the deadliest in decades.
The incoming Dutch government, led by Prime Minister-designate Rob Jetten, has unveiled its policy agenda, pledging continued military and financial support for Ukraine and a commitment to enshrine higher NATO defense spending targets into law.
President Donald Trump has nominated Kevin Warsh, a former Federal Reserve governor and critic of current monetary policy, to succeed Jerome Powell as Chair of the Federal Reserve, setting the stage for a potential shift in the central bank's direction.
While rising prices are felt at the checkout line, their long-term erosion of retirement savings is often overlooked. Experts warn that cumulative inflation across essential categories could create a six-figure shortfall for unprepared retirees.
The long-term strategic partnership will leverage IQVIA's data-as-a-service platform to unify and streamline commercial data across 59 countries, aiming to accelerate product launches and enhance decision-making for the pharmaceutical giant.
With major indices hovering near record levels and the Federal Reserve on hold, income-focused investors are turning to dividend payers for reliable returns. We analyze three standout stocks offering yields and stability as the market awaits tech earnings season.
